In such a scenario, the expression level of ADORA3 in tumor tissues might be an essential prerequisite for identifying patients that benefit from this approach due to our observation of quite variable ADORA3 levels in HCC- and CCA-derived patient samples. This evidence concerns the gene ADORA3 and hepatocellular carcinoma.